Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: A randomized, controlled trial
Journal of Acquired Immune Deficiency Syndromes, ISSN: 1525-4135, Vol: 64, Issue: 3, Page: 279-283
2013
- 41Citations
- 54Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations41
- Citation Indexes41
- 41
- CrossRef27
- Captures54
- Readers54
- 54
- Mentions1
- Blog Mentions1
- Blog1
Most Recent Blog
HIV Antiretroviral Therapy: Also Anti-Kidney?
When consulted by your infectious disease colleagues as to the cause of new or worsening renal impairment in a patient with human immunodeficiency virus (HIV), the differential is broad but changing. The classic HIV-associated collapsing glomerulopathy has become less common in the era of combined antiretroviral therapy (cART) and the prevalence of other kidney disease in persons with HIV has incr
Article Description
We performed a randomized controlled trial in 30 HIV-infected participants to either continue tenofovir/emtricitabine/efavirenz (Continuation Group) or switch to tenofovir/emtricitabine/raltegravir (Switch Group) for 24 weeks. There were no significant differences in the changes in flow-mediated dilation, 25(OH) vitamin D, or parathyroid hormone levels. Total cholesterol, high sensitivity C-reactive protein, serum alkaline phosphatase, sCD14 levels, and renal function significantly declined in the Switch Group compared with the Continuation Group; however, sCD163 levels significantly increased in the Switch Group. These findings suggest that raltegravir is not inherently more beneficial to endothelial function compared with efavirenz but may impact renal function and monocyte activation. Copyright © 2013 by Lippincott Williams & Wilkins.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84886387920&origin=inward; http://dx.doi.org/10.1097/qai.0b013e3182a97c39; http://www.ncbi.nlm.nih.gov/pubmed/24278992; https://journals.lww.com/00126334-201311010-00008; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00126334-201311010-00008; https://dx.doi.org/10.1097/qai.0b013e3182a97c39; https://journals.lww.com/jaids/Fulltext/2013/11010/Effects_of_Switching_From_Efavirenz_to_Raltegravir.8.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know